Clinical trials: Recurrent High Grade Glioma, open to volunteers
High Grade Glioma
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week.
- Trial name
- NCT04254419
- Testing
- NK cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Nationwide Children's Hospital
Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults.
- Trial name
- NCT06305910
- Testing
- Treatment with CD200AR-L
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OX2 Therapeutics
Recurrent Glioblastoma
An Optimization Study Evaluating Safety and Efficacy of the Y-90 Glioblastoma (GBM) Device in Patients With Recurrent GBM
The purpose of this study is to test Y90 glass microspheres for people with recurrent brain cancer. Participation in this study will help researchers find the best dose for the treatment of the disease.
- Trial name
- ODYSSEY (NCT07867886)
- Testing
- Device: TheraSphere GBM treatment of TheraSphere GBM device
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Boston Scientific Corporation
High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG)
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.
- Conditions
- High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
- Trial name
- NCT07455045
- Testing
- FZ-AD005
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
High-grade Glioma
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
The clinical protocol plans to preset three dose groups, namely 1×10⁷ cells per dose, 3×10⁷ cells per dose, and 6×10⁷ cells per dose.
- Trial name
- NCT06737146
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Glioblastoma
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
- Trial name
- NCT05917145
- Testing
- WSD0628
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Mayo Clinic
Recurrent High Grade Glioma
Recurrent High Grade Glioma Treated by LITT
This clinical trial aims to investigate the efficiency and safety of laser interstitial thermal therapy (LITT) in recurrent high-grade glioma (rHGG) patients.
- Trial name
- REGALITT (NCT06161610)
- Testing
- LITT, Control
- Where
- 9 sites in China
- Volunteers
- 135 people
- Sponsor
- Beijing Tiantan Hospital
High Grade Glioma, Ependymoma
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.
- Conditions
- High Grade Glioma, Ependymoma, Embryonal Tumor of Brain, Recurrence
- Trial name
- PED-DNX2401 (NCT07424092)
- Testing
- DNX-2401
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 39 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Glioma, Malignant
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain…
- Trial name
- NCT04547777
- Testing
- D2C7-IT, 2141-V11
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Darell Bigner
High Grade Glioma, Glioblastoma
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been…
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT07859059
- Testing
- Dexbrompheniramine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Nebraska
Brain Gliomas, High-Grade Gliomas
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
B7-H3 is expressed at low levels in normal tissues but overexpressed in various tumor tissues. The ubiquitous expression of B7-H3 in tumors of different grades is a key feature for brain gliomas.
- Conditions
- Brain Gliomas, High-Grade Gliomas, GBM
- Trial name
- NCT06018363
- Testing
- Allogenic B7-H3 CAR-γδT cell(QH104)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Dushu Lake Hospital Affiliated to Soochow University
Recurrent High Grade Glioma, Anaplastic Astrocytoma
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years.
- Conditions
- Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
- Trial name
- NCT05698524
- Testing
- PCI 24781, Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Nebraska
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
A Study of NST-628 in Recurrent Grade 4 Glioma
This is an open-label, single arm, non-randomized, Phase 0 and expansion Phase 1 study of NST-628 in adult patients with recurrent Grade 4 glioma with high phosphorylated extracellular signal-regulated kinase (pERK) expression…
- Trial name
- NCT07784985
- Testing
- NST-628
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nader Sanai
Solid Tumor Cancer, Medulloblastoma
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
- Conditions
- Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas
- Trial name
- LUPARPED (NCT06607692)
- Testing
- Olaparib; 177Lu-DOTATATE
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Fundación de investigación HM
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
This phase I trial tests the safety, side effects and best dose of TGFβR2KO/IL13Rα2 chimeric antigen receptor (CAR) T-cells given within the skull (intracranial) in treating patients with glioblastoma or IDH-mutant grade 3 or 4…
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
- Trial name
- NCT06815029
- Testing
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, High-Grade Gliomas
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups.
- Conditions
- Glioblastoma, High-Grade Gliomas, Grade III Astrocytoma, Grade III Glioma
- Trial name
- NCT06975332
- Testing
- Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)
- Where
- 2 sites in Poland
- Volunteers
- 35 people
- Sponsor
- Medical University of Warsaw
Malignant Glioma of Brain, Astrocytoma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent…
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor
- Trial name
- NCT05686798
- Testing
- Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Henry Ford Health System
Recurrent High Grade Glioma
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhanced delivery (CED) in…
- Trial name
- PuMP (NCT06126744)
- Testing
- MVR-C5252
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
HGG, High Grade Glioma (III or IV)
A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma
The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.
- Conditions
- HGG, High Grade Glioma (III or IV), High Grade Glioma
- Trial name
- NCT07710690
- Testing
- NRG-103
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Neuregen Therapeutics Co., Ltd.